▲ Peaking
Business
Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets
Addex spinout Neurosterix secures $105M Series B to advance a Phase 2 schizophrenia trial, recruiting veterans from Karuna Therapeutics' Cobenfy program.